Last reviewed · How we verify
stander treatment pregabalin
Pregabalin binds to the alpha-2-delta subunit of voltage-gated calcium channels in the central nervous system, reducing the release of excitatory neurotransmitters.
Pregabalin binds to the alpha-2-delta subunit of voltage-gated calcium channels in the central nervous system, reducing the release of excitatory neurotransmitters. Used for Neuropathic pain (diabetic peripheral neuropathy, postherpetic neuralgia, spinal cord injury), Partial-onset seizures (adjunctive therapy), Generalized anxiety disorder.
At a glance
| Generic name | stander treatment pregabalin |
|---|---|
| Sponsor | Hawler Medical University |
| Drug class | Gabapentinoid; anticonvulsant; anxiolytic |
| Target | Alpha-2-delta subunit of voltage-gated calcium channels |
| Modality | Small molecule |
| Therapeutic area | Neurology; Pain Management; Psychiatry |
| Phase | FDA-approved |
Mechanism of action
By binding to presynaptic calcium channels, pregabalin decreases calcium influx and subsequently reduces the release of glutamate, noradrenaline, and substance P. This leads to reduced neuronal excitability and pain signal transmission. The drug is effective in conditions characterized by neuropathic pain and hyperexcitability of the nervous system.
Approved indications
- Neuropathic pain (diabetic peripheral neuropathy, postherpetic neuralgia, spinal cord injury)
- Partial-onset seizures (adjunctive therapy)
- Generalized anxiety disorder
- Fibromyalgia
Common side effects
- Dizziness
- Somnolence
- Dry mouth
- Edema (peripheral)
- Weight gain
- Blurred vision
- Ataxia
Key clinical trials
- Thymoquinone as an add-on Therapy for the Management of Patients With Diabetic Peripheral Neuropathy (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- stander treatment pregabalin CI brief — competitive landscape report
- stander treatment pregabalin updates RSS · CI watch RSS
- Hawler Medical University portfolio CI